(1E, 4E, 6E)-1-(3, 5-dimethoxyphenyl)-7-(4-hydroxy-3, 5 dimethoxyphenyl) hepta-1, 4, 6-trien-3-one
Chronic Low Back Pain
Frontier Biotechnologies Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
6 Active assets in the Chronic Low Back Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DICLOFENAC Organon and Co | Phase 4 | BB |
Etoricoxib Organon and Co | Phase 4 | BB |
Sra-333 Wake Forest University | Phase 4 | B |
Dfn-15 Endo USA Inc., a Keenova Therapeutics Company | Phase 4 | B |
Tapentadol Janssen Scientific Affairs, LLC | Phase 4 | B |
View all 15 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →